[go: up one dir, main page]

PL3897636T3 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith - Google Patents

Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Info

Publication number
PL3897636T3
PL3897636T3 PL19901383.0T PL19901383T PL3897636T3 PL 3897636 T3 PL3897636 T3 PL 3897636T3 PL 19901383 T PL19901383 T PL 19901383T PL 3897636 T3 PL3897636 T3 PL 3897636T3
Authority
PL
Poland
Prior art keywords
aminophenyl
piperidine
amino
substituted
compositions
Prior art date
Application number
PL19901383.0T
Other languages
Polish (pl)
Inventor
Massimo AMMIRANTE
Sogoie BAHMANYAR
Matthew D. Correa
Virginia GRANT
Joshua Hansen
Evan J. Horn
Timothy S. Kercher
Christopher Mayne
Mark A. Nagy
Rama Krishna Narla
Surendra NAYAK
Stephen Norris
Patrick Papa
Veronique Plantevin-Krenitsky
John J. Sapienza
Brandon W. Whitefield
Shuichan SU
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of PL3897636T3 publication Critical patent/PL3897636T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94Oxygen atom, e.g. piperidine N-oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL19901383.0T 2018-12-19 2019-12-18 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith PL3897636T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782298P 2018-12-19 2018-12-19
US201962879900P 2019-07-29 2019-07-29
PCT/US2019/067088 WO2020132014A1 (en) 2018-12-19 2019-12-18 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
PL3897636T3 true PL3897636T3 (en) 2025-04-28

Family

ID=71098067

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19901383.0T PL3897636T3 (en) 2018-12-19 2019-12-18 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Country Status (30)

Country Link
US (3) US11149007B2 (en)
EP (2) EP4494711A3 (en)
JP (2) JP7494181B2 (en)
KR (2) KR20250144505A (en)
CN (2) CN119219606A (en)
AU (1) AU2019403207B2 (en)
BR (1) BR112021011968A2 (en)
CA (1) CA3124130A1 (en)
CL (1) CL2021001665A1 (en)
CO (1) CO2021007973A2 (en)
DK (1) DK3897636T3 (en)
ES (1) ES3009308T3 (en)
FI (1) FI3897636T3 (en)
HR (1) HRP20250095T1 (en)
HU (1) HUE070506T2 (en)
IL (1) IL284223B2 (en)
LT (1) LT3897636T (en)
MX (1) MX2021007473A (en)
MY (1) MY205718A (en)
NZ (1) NZ777281A (en)
PE (1) PE20212247A1 (en)
PL (1) PL3897636T3 (en)
PT (1) PT3897636T (en)
RS (1) RS66556B1 (en)
SG (1) SG11202106507RA (en)
SI (1) SI3897636T1 (en)
SM (1) SMT202500111T1 (en)
TW (1) TWI820276B (en)
WO (1) WO2020132014A1 (en)
ZA (1) ZA202104200B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102864064B1 (en) 2018-12-19 2025-09-24 셀진 코포레이션 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and therapeutic methods using the same
FI3897636T3 (en) * 2018-12-19 2025-02-03 Celgene Corp Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
MX2022014071A (en) 2020-05-09 2023-01-30 Arvinas Operations Inc Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same.
CN115835866B (en) 2020-06-24 2025-05-02 新基公司 Cereblon binding compounds, compositions thereof, and methods of use thereof
US11739075B2 (en) 2020-06-24 2023-08-29 Celgene Corporation Cereblon binding compounds, compositions thereof, and methods of treatment therewith
JP7781083B2 (en) 2020-06-24 2025-12-05 セルジーン コーポレーション Cereblon-binding compounds, compositions thereof, and methods of treatment therewith
CA3186548A1 (en) * 2020-07-21 2022-01-27 Song Hee Lee Compound for androgen receptor degradation, and pharmaceutical use thereof
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (en) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
KR20230157936A (en) 2020-12-14 2023-11-17 바이오테릭스, 인코포레이티드 PDE4 degrading factors, pharmaceutical compositions, and therapeutic applications
CN116940568A (en) * 2021-03-17 2023-10-24 南京明德新药研发有限公司 Furan condensed ring substituted glutarimides
JP2024526191A (en) * 2021-06-25 2024-07-17 セルジーン コーポレーション Cereblon-binding compounds, compositions thereof and methods of treatment therewith
US20250100995A1 (en) * 2021-06-25 2025-03-27 Celgene Corporation Cereblon binding compounds, compositions thereof, and methods of treatment therewith
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
JP2025537273A (en) * 2022-11-09 2025-11-14 ブリストル-マイヤーズ スクイブ カンパニー Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds
WO2025235577A1 (en) * 2024-05-09 2025-11-13 Bristol-Myers Squibb Company Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds
CN118993935B (en) * 2024-10-23 2025-02-14 江苏恒瑞医药股份有限公司 Preparation method of imidazoline derivative or its salt

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302485A1 (en) 1993-01-29 1994-08-04 Merck Patent Gmbh Piperazine derivatives
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
FR2768729A1 (en) 1997-09-19 1999-03-26 Rhodia Chimie Sa A new process for the acylation of an aromatic compound
FR2768728B1 (en) 1997-09-19 1999-12-03 Rhodia Chimie Sa PROCESS FOR ACYLATION OF AN AROMATIC COMPOUND
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
CN101676270A (en) 2004-09-09 2010-03-24 中外制药株式会社 Novel tetrahydroimidazole derivatives and use thereof
WO2007044804A2 (en) 2005-10-11 2007-04-19 Chemocentryx, Inc. Piperidine derivatives and methods of use
WO2007136640A2 (en) * 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
RU2434851C1 (en) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Cyclic n,n'-diarylthioureas or n,n'-diarylureas - antagonists of androgen receptors, anti-cancer medication, method of obtaining and application
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
CA2829322C (en) 2011-03-10 2017-01-10 Suzhou Kintor Pharmaceuticals, Inc. Substituted thioimidazolidinone androgen receptor antagonists and uses thereof
US20140112922A1 (en) 2011-03-28 2014-04-24 Cornell University Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes
KR102438072B1 (en) 2012-01-12 2022-08-31 예일 유니버시티 Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase
RU2639145C2 (en) 2012-09-04 2017-12-20 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Oxothioimidazoline derivatives, methods for their production and application in medicine as androgen receptor inhibitors
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
KR102226587B1 (en) 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 Quinoline and quinazoline amides as modulators of sodium channels
KR20250127179A (en) 2014-04-14 2025-08-26 아비나스 오퍼레이션스, 인코포레이티드 Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
RU2557235C1 (en) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Substituted 2-thioxo-imidazolidin-4-one, and spiroanalogues thereof, anticancer active ingredient, pharmaceutical composition, medicinal product, method of treating prostate cancer
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (en) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド How to Induce Targeted Proteolysis by Bifunctional Molecules
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
HK1249058A1 (en) 2015-03-18 2018-10-26 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2988430A1 (en) 2015-07-10 2017-01-19 Arvinas, Inc. Mdm2-based modulators of proteolysis and associated methods of use
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. CARBON-BONDED GLUTARIMIDE-TYPE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
WO2018009694A1 (en) * 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Thiohydantoin androgen receptor antagonists for the treatment of cancer
TWI739888B (en) 2016-10-07 2021-09-21 美商陶氏農業科學公司 Pesticidal compositions and methods
HUE070289T2 (en) 2016-10-11 2025-05-28 Arvinas Operations Inc Compounds and methods for the targeted degradation of androgen receptor
US10925868B2 (en) 2016-11-10 2021-02-23 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
EP3544957B1 (en) 2016-11-22 2024-05-29 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
TWI725266B (en) 2016-12-19 2021-04-21 大陸商上海和譽生物醫藥科技有限公司 FGFR4 inhibitor, its preparation method and pharmaceutical application
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREBLON LIGANDS AND BIFUNCTIONAL CONNECTIONS THEREOF
CN118440096A (en) 2017-06-20 2024-08-06 C4医药公司 Degradation stator and degradation determinant for N/O-ligation of protein degradation
CN109422725A (en) 2017-09-04 2019-03-05 北京美倍他药物研究有限公司 Drugs for prostate cancer
ES2959954T3 (en) 2017-11-28 2024-02-29 Aarti Pharmalabs Ltd Process for the preparation of enzalutamide using a new intermediate
US20210380576A1 (en) 2017-12-05 2021-12-09 Dow Agrosciences Llc Pesticidal compositions and methods
WO2019228341A1 (en) 2018-05-30 2019-12-05 江苏豪森药业集团有限公司 Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
CN109651256A (en) 2018-11-20 2019-04-19 上海健康医学院 A kind of preparation method of the miscellaneous Shandong amine of the grace of formula (VIII)
FI3897636T3 (en) 2018-12-19 2025-02-03 Celgene Corp Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
KR102864064B1 (en) * 2018-12-19 2025-09-24 셀진 코포레이션 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and therapeutic methods using the same

Also Published As

Publication number Publication date
WO2020132014A1 (en) 2020-06-25
TWI820276B (en) 2023-11-01
CA3124130A1 (en) 2020-06-25
MX2021007473A (en) 2021-08-05
IL284223B1 (en) 2025-04-01
MY205718A (en) 2024-11-07
FI3897636T3 (en) 2025-02-03
KR20210118816A (en) 2021-10-01
NZ777281A (en) 2025-07-25
CN119219606A (en) 2024-12-31
PT3897636T (en) 2025-01-27
US11149007B2 (en) 2021-10-19
JP2024109765A (en) 2024-08-14
SI3897636T1 (en) 2025-04-30
TW202039435A (en) 2020-11-01
US20240368083A1 (en) 2024-11-07
HUE070506T2 (en) 2025-06-28
SG11202106507RA (en) 2021-07-29
KR102866144B1 (en) 2025-09-30
CN113453681B (en) 2024-10-11
SMT202500111T1 (en) 2025-05-12
EP4494711A2 (en) 2025-01-22
AU2019403207A1 (en) 2021-07-15
KR20250144505A (en) 2025-10-10
CO2021007973A2 (en) 2021-09-09
BR112021011968A2 (en) 2021-09-08
CN113453681A (en) 2021-09-28
PE20212247A1 (en) 2021-11-24
US20200199073A1 (en) 2020-06-25
LT3897636T (en) 2025-03-25
RS66556B1 (en) 2025-03-31
EP4494711A3 (en) 2025-05-21
IL284223A (en) 2021-08-31
JP2022514344A (en) 2022-02-10
JP7724911B2 (en) 2025-08-18
HRP20250095T1 (en) 2025-04-11
ES3009308T3 (en) 2025-03-26
US11873283B2 (en) 2024-01-16
US20230002321A1 (en) 2023-01-05
EP3897636A4 (en) 2022-09-07
US12404241B2 (en) 2025-09-02
IL284223B2 (en) 2025-08-01
ZA202104200B (en) 2024-11-27
DK3897636T3 (en) 2025-01-13
JP7494181B2 (en) 2024-06-03
CL2021001665A1 (en) 2022-01-14
EP3897636B1 (en) 2024-12-11
EP3897636A1 (en) 2021-10-27
AU2019403207B2 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
ZA202104200B (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
SG11202106506WA (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
IL288278A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
ZA202000208B (en) 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MY205416A (en) Tyk2 inhibitors and uses thereof
MX2018009773A (en) Heteroaryl inhibitors of pad4.
IL262007A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
SG11202105730TA (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
SG11202001756YA (en) Compositions, uses and methods for treatment of infertility and subfertility
ZA202007320B (en) Compounds for pain treatment, compositions comprising same, and methods of using same
HK40061384A (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
IL268318A (en) Compounds, compositions and uses thereof for improvement of bone disorders
SI3849970T1 (en) Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof
WO2015138186A3 (en) Methods and compositions for treating anthracycline-induced cardiomyopathy using neurokinin-1 receptor antagonists
HK40102343A (en) Oral compositions for the treatment of gastroesophageal reflux
HK40068676A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
IL284350A (en) Domperidone compositions and methods for treating depression
EA202191713A1 (en) SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, THEIR COMPOSITIONS AND THEIR TREATMENT METHODS
TW202547839A (en) Tyk2 inhibitors and uses thereof
EA202191712A1 (en) SUBSTITUTED 3 - ((3-AMINOPHENYL) AMINO) PIPERIDINE-2,6-DIONE COMPOUNDS, THEIR COMPOSITIONS AND METHODS OF TREATMENT WITH THEIR
HK40033885A (en) Compositions, uses and methods for treatment of infertility and subfertility